Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05847686 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT05847686 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 55 participants.
The verdict
NCT05847686, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment of anxiety and depression in patients with cancer. In this study, the psilocybin being used is derived from the mushroom psilocybe cubensis using a patented process that results in a pharmaceutical grade version of psilocybin. Psilocybin acts by activating serotonin receptors on brain cells which can change perceptions and patterns of thinking in ways that may decrease anxiety.
Interventions
- OTHER Questionnaire Administration
- DRUG Psilocybin
- OTHER Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05847686
The ClinicalTrials.gov registry entry for NCT05847686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT05847686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05847686 about?
NCT05847686 is a clinical study titled "Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer". This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment of anxiety and depre...
What is the current status of trial NCT05847686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2023-06-27. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT05847686?
The interventions under investigation include: Questionnaire Administration (OTHER), Psilocybin (DRUG), Counseling (OTHER).
Who is sponsoring clinical trial NCT05847686?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.